Profiel
Rob Ortmann worked as an Executive Director of Clinical Development at Horizon Therapeutics Plc from 2021 to 2022.
Prior to that, he worked as the Head of US Immunology at AstraZeneca PLC.
He holds a doctorate degree from Case Western Reserve University School of Medicine.
Eerdere bekende functies van Rob Ortmann
Bedrijven | Functie | Einde |
---|---|---|
HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Hoofd Techniek/Wetenschap/O&O | 01-05-2022 |
ASTRAZENECA PLC | Corporate Officer/Principal | - |
Opleiding van Rob Ortmann
Case Western Reserve University School of Medicine | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
ASTRAZENECA PLC | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
Horizon Therapeutics Plc
Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. | Health Technology |